This isn't surprising, as the days of single-locus disease discoveries are largely behind us, but this is just one small factor among many. It can hint at functional things, but mostly it's another landmark for risk-screening.
> NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity. Our results provide new and important insights into ALS etiopathogenesis and genetic etiology.
This is basically a grab-bag. I wouldn't expect any kind of applied research based on this for another grant cycle or two.
It costs $145000 per year in the US and $35000 per year in Japan. It slows down the progression of the disease in a specific subset of patients (early stages of the disease with rapid progression of symptoms) which comprises approximately 7% of people with ALS. Trials among a general ALS population failed to show any efficacy.
https://www.healthnewsreview.org/2017/09/facts-about-the-new...